Lazard Asset Management
AKCA

Lazard Asset Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Lazard Asset Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,731
Closed -$67K – 1836
2020
Q1 		$67K Buy
+4,731
New +$77.7K ﹤0.01% 1096

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lazard Asset Management's AKCA Position: Q2 2020 in Review

Lazard Asset Management sold out of Akcea Therapeutics Inc (AKCA) in Q2 2020, closing a stake of 4,731 shares — an estimated $67K sold.

Lazard Asset Management first reported a position in AKCA in Q1 2020 and held it in 1 quarter. The position peaked at $67K in Q1 2020. 84 funds tracked by Wall St. Rank hold AKCA as of Q2 2020.

  • Lazard Asset Management reported no remaining Akcea Therapeutics Inc position as of Q2 2020 after selling out during the quarter.
  • Lazard Asset Management sold 4,731 Akcea Therapeutics Inc shares in Q2 2020, an estimated $67K.
  • Lazard Asset Management first reported a position in Akcea Therapeutics Inc in Q1 2020 and held it in 1 quarter.
  • Lazard Asset Management's Akcea Therapeutics Inc position peaked at $67K in Q1 2020.
  • 84 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2020.

Based on Lazard Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.